Beghou

Name: Beghou
Address: 909 Davis Street, Suite 650, Evanston, IL, 60201, US
Telephone: +18478645480
Price range: $$

A long-term, agile partner for life sciences commercialization. Our work is data-driven and quantitative.

Beghou Consulting is a management consulting firm focusing on sales and marketing issues in the pharmaceutical and biotech industries. Our consultants bring extensive industry experience, proven modeling methods, and data management skills. We seek to develop and apply state-of-the art analytic models to address critical issues. While we perform most of our work in our offices, our consultants hav

e a high degree of client contact. We work closely with client management during all phases of our projects to ensure that our recommendations and solutions have broad organizational support. Our dynamic, entrepreneurial and collaborative environment provides a unique blend of intense dedication to our clients with a casual work atmosphere that results in long-term client relationships. We pride ourselves in exceeding expectations by treating our clients like we would want to be treated and providing flexibility in all our engagements.

08/31/2026

We're excited to welcome Kunal Hande to Beghou as Associate Partner, based in our Pune, India office.

Kunal brings over a decade of experience in life sciences consulting, with a deep focus on sales force effectiveness across the product lifecycle.

His expertise spans patient journey mapping, field force strategy, targeting and segmentation, sales force sizing, incentive compensation design, and performance reporting, giving him a comprehensive view of what it takes to make commercial teams perform at their best.

His therapeutic area experience includes oncology, gastroenterology, respiratory, and rare diseases, with a strong track record across multiple product launches and field optimization engagements.

Before joining Beghou, Kunal held consulting roles at IQVIA and ZS.

At Beghou, he will partner with life sciences clients to build and optimize commercial roles and structures that enable more effective customer engagement and support better patient outcomes.

Welcome to the team, Kunal!

08/28/2026

We’re delighted to be a sponsor of Fierce Pharma Week this year!

We look forward to four days of game-changing ideas and sharp takes across pharma marketing, medical affairs, commercialization, and communications.

Beghou’s Clare Gora will be one of the expert presenters talking about commercialization strategy in the age of AI — details coming soon.

📅 September 14 – 17, 2026

📍 Pennsylvania Convention Center

If you’re planning to attend, do stop by Booth #516 and say hello!

Register here: https://hubs.ly/Q04vH4q70

08/27/2026

“You don’t have the time, and you don’t have the resources, to mess it up.”

That’s how commercial operations leader Lori Nemyier describes the pressure emerging biotech and biopharma companies face as they approach launch.

But the pressure isn’t simply getting to market.

Reaching launch and winning at launch are two different things, which means companies also need to be prepared to execute flawlessly from day one.

That distinction puts commercial ops at the center of the conversation. Decisions about the operating model, data, ex*****on complexity, and organizational cohesion can shape whether a therapy reaches patients efficiently or struggles to gain traction.

In conversation with Marc Iskowitz on The Space Life Sciences Podcast, Lori shares four strategies for a successful launch.

08/26/2026

“The industry has learned some lessons over the last couple years in terms of being pickier with capital investment decisions. I don’t think that’s going to change.”

After a few difficult years for biotech financing, companies have become more selective about investment decisions and more disciplined about capital efficiency. For Jacob Lai this discipline is likely here to stay, even amidst the current biotech boom.

That means being careful about how capital is deployed at different stages of commercialization. Jacob shares his perspective on some of the decisions involved, including his biggest piece of advice for emerging biotechs.

Hear more from Jacob in his conversation with Marc Iskowitz in the full podcast episode https://hubs.ly/Q04vnq8H0

08/21/2026

What if you could market AI adoption to your team by segmenting them into personas the same way you market to HCPs or patients?

That's the premise behind Beghou's survey of 100 biopharma and pharma professionals on their personal and organizational AI readiness.

A primary finding: commercial team members are already experimenting with tools like Copilot and ChatGPT on their own but haven’t integrated them into their workflows yet.

Just like HCPs and patients, team members don't all respond to the same message. The survey surfaced eight distinct AI adoption personas across the workforce.

Five stood out as the highest-impact opportunities for targeted intervention:

➡️ The Governor, who values safety, compliance, transparency, and process and is concerned about responsible organization use

➡️ The Enthusiast, whose excitement outpaces their grasp of what implementation actually takes

➡️ The Anxious Skeptic, who is worried about being replaced or being devalued

➡️ The ROI-er, who is unwilling to back AI without a business case and numbers to prove its value

➡️ The Swamped, who isn't against AI but is just too buried to add one more thing

Understanding these provides the basis for meeting people where they are to convert experimentation into supported, repeatable ways of working.

08/20/2026

Data investment decisions can become overwhelming quickly.

There may be dozens of sources to consider, different stakeholders pushing for different priorities, and no simple way to compare the potential value of one option against the effort required to put it to use.

One way to bring more structure to the decision is to look at each option across three dimensions:

1. 𝗘𝘅𝗽𝗲𝗰𝘁𝗲𝗱 𝗯𝘂𝘀𝗶𝗻𝗲𝘀𝘀 𝗶𝗺𝗽𝗮𝗰𝘁: What could this data help the organization do better?
2. 𝗜𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝗹𝗲𝘃𝗲𝗹: What will it take to acquire, integrate, analyze, and maintain?
3. 𝗙𝗲𝗮𝘀𝗶𝗯𝗶𝗹𝗶𝘁𝘆: Can it realistically be put it into practice?

From there, the options tend to fall into four groups:

💠 𝗤𝘂𝗶𝗰𝗸 𝘄𝗶𝗻𝘀 𝘄𝗼𝗿𝘁𝗵 𝗽𝗿𝗶𝗼𝗿𝗶𝘁𝗶𝘇𝗶𝗻𝗴

High-impact opportunities that require relatively limited investment.
For example, better integration of existing data may improve targeting and patient identification without requiring a major new purchase.

💠 𝗪𝗼𝗿𝘁𝗵 𝘁𝗵𝗲 𝗶𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝗶𝗳 𝘁𝗵𝗲 𝘂𝗽𝘀𝗶𝗱𝗲 𝗶𝘀 𝗺𝗲𝗮𝗻𝗶𝗻𝗴𝗳𝘂𝗹

Some higher investment opportunities can still have a strong business case.
A $1 million dataset, for example, may be worthwhile if it helps identify 10 additional patients for a $500,000 therapy.

💠 𝗜𝗻𝗰𝗿𝗲𝗺𝗲𝗻𝘁𝗮𝗹 𝗶𝗺𝗽𝗿𝗼𝘃𝗲𝗺𝗲𝗻𝘁𝘀

Lower-impact options may still make sense when they are inexpensive and operationally simple to implement.

💠 𝗛𝗮𝗿𝗱 𝘁𝗼 𝗷𝘂𝘀𝘁𝗶𝗳𝘆

Higher investment options become much more difficult to defend when they add only marginal visibility or do not materially change decisions.

This decision framework can help make the tradeoffs clearer and focus decisions on where the expected impact is proportionate to the investment required.

See how to apply the framework: https://hubs.ly/Q04tH4v80

08/17/2026

You know your current datasets aren’t surfacing all potential patients with the rare disease your therapy addresses. But will adding another dataset actually help?

Signals for patients with a rare disease can be scattered across complex pathways and years of care. Before investing, it can be helpful to step back and determine what is limiting visibility of the right patients, such as:

𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰 𝘀𝗶𝗴𝗻𝗮𝗹𝘀: Can you detect the markers and events that distinguish the patient journey?
𝗖𝗮𝗿𝗲 𝘁𝗲𝗮𝗺 𝗰𝗼𝗻𝘁𝗲𝘅𝘁: Can you identify the HCPs and organizations shaping their journey?
𝗗𝗮𝘁𝗮 𝗰𝗼𝗺𝗽𝗹𝗲𝘁𝗲𝗻𝗲𝘀𝘀: Are parts of the journey missing across care settings or data sources?
𝗜𝗻𝘀𝗶𝗴𝗵𝘁 𝗹𝗶𝗺𝗶𝘁𝗮𝘁𝗶𝗼𝗻: Are you missing clinical detail, coverage, or connections across sources?

A decision framework can help assess the gap and identify potential responses:

𝗠𝗶𝘀𝘀𝗶𝗻𝗴 𝗱𝗮𝘁𝗮: stacking on another claims dataset
𝗜𝗻𝘀𝘂𝗳𝗳𝗶𝗰𝗶𝗲𝗻𝘁 𝗰𝗼𝗻𝘁𝗲𝘅𝘁: adding unstructured data sources
𝗔𝗻𝗮𝗹𝘆𝘁𝗶𝗰𝘀 𝗰𝗮𝗽𝗮𝗯𝗶𝗹𝗶𝘁𝗶𝗲𝘀: a different approach or better connections of existing sources

This gives teams a practical way to compare options and determine if added data, enrichment, linkage, or analytic refinement is most likely to improve identification of the right patients.

08/14/2026

What are some practical, high-impact AI use cases that are moving the needle for today’s field teams? Join our roundtable at the COM-X 2026 Summer Summit on leveraging AI to activate the rep of the future.

📍San Diego Tech CenterSan Diego, CA

🕕 August 20, 2:00–3:00 PM PST

Beghou Partners Nicole Ventrone, Vishal Singal, Dennis Fournogerakis, will host the discussion. Building on survey data and real-world examples, they’ll discuss how organizations are seeing value from use cases such as:

💠Synthesizing med affairs notes
💠Improving NBA guidance
💠Prioritizing the right HCPs
💠Generating more timely performance insights

We’d love to see you at the roundtable and at the networking reception afterward.

Reserve your spot: https://hubs.ly/Q04sZcxd0

08/13/2026

Before investing in more data for KOL identification, it’s important to define what “influence” means for the indication of interest. This makes it easier to identify the data sources needed to capture the relevant dimensions of influence.

For example, finding the right KOLs in Alzheimer’s disease relies on understanding how physicians contribute across multiple dimensions:

• Clinical decision-making and referral patterns
• Treatment awareness
• Care pathway shaping
• Research and publications
• Engagement with advocacy and community groups

Claims data alone often does not provide enough detail.

In complex and evolving treatment landscapes like Alzheimer’s disease, a more complete view of KOL influence often requires multiple data types:

• ClinicalTrials.gov
• Journal publications
• EHR data
• Medicare data
• Social media
• Advocacy organizations
• Specialty pharmacy data
• Hub data

Mapping a multidimensional view of influence for the specific indication before investing in more data sources helps clarify whether the data will add value and aid with identifying the right KOLs.

For a pragmatic framework for life sciences leaders before investing in more data, here's the webinar link: https://hubs.ly/Q04sX56X0

Address

909 Davis Street, Suite 650
Evanston, IL
60201

Telephone

+18478645480

Website

http://beghou.com/

Alerts

Be the first to know and let us send you an email when Beghou posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Beghou:

Want your business to be the top-listed Business in Evanston?